Kristian Daniel Ralph Roth

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutations

S. Dübel, G. Roth, K. Eschke, 2020, bioRxiv.